Formulations That Meet Unmet Patient Needs

Focused on long acting
depot injections

Developing Finished Dosage Forms and a Portfolio of APIs

Fully integrated GMP
manufacturing facilities

Pipeline of Multiple Late Stage Products

In Phase III for RMS and Phase II for
PPMS for treating MS

Mapi Pharma

We are a clinical stage pharmaceutical company, developing complex active pharmaceutical ingredients.


Our main focus is on developing long acting depot injectable drugs.


Our lead programs are GA Depot for treating various forms of MS and long acting Pregabalin (Lyrica®) for pain.

Latest News

Jingxin 30th Anniversary Greeting from Mapi Pharma

NESS ZIONA, Israel, September 30, 2020 -- Mapi Pharma Ltd., a privately held, fully integrated, late clinical stage biopharmaceutical company today greets its partner, Zhejiang Jingxin Pharmaceutical Co Ltd.   To our friends and partners at Jingxin Pharma, On...